Journal of Nuclear Medicine | |
Whole-Body 18F-FDG PET and Conventional Imaging for Predicting Outcome in Previously Treated Breast Cancer Patients | |
Michael E. Phelps1  Daniel H. Silverman1  Johannes Czernin1  Duska Vranjesevic1  Joubin Meta1  Peter E. Valk1  Jean Emmanuel Filmont1  Jyotsna Rao1  | |
关键词: breast cancer; 18F-FDG PET; patient outcome; conventional imaging; | |
DOI : | |
学科分类:医学(综合) | |
来源: Society of Nuclear Medicine | |
【 摘 要 】
This study was conducted to determine the ability of 18F-FDG PET and conventional imaging (CI) to predict the outcomes in breast cancer patients who have previously undergone primary treatment. Methods: The study population consisted of 61 female patients (median age, 54 y; range, 32–91 y) who were reevaluated with 18F-FDG PET and CI after treatment. The median interval between the last treatment and PET was 0.4 y (range, 0–16 y). PET was performed within 3 mo of CI (median interval, 25 d; range, 2–84 d). To determine the independent impact of PET on outcome, PET images were reinterpreted in a blind fashion. Availability of clinical information after PET scanning (21 ± 12 mo) was required for study inclusion. Study endpoints were clinical evidence of progression of disease or death. Results: Of 61 patients, 19 (31.1%) had no clinical evidence and 38 (62.3%) had evidence of residual or recurrent disease by the end of follow-up. Four patients (6.6%) had died. The positive and negative predictive values (PPV and NPV, respectively) of PET were 93% and 84%, respectively. CI yielded a PPV of 85% and an NPV of 59%. The prognostic accuracy of single whole-body PET was superior to that of multiple procedures with CI (90% vs. 75%; P < 0.05). Kaplan–Meier estimates of disease-free survival in patients with negative PET findings compared with those with positive PET findings revealed a significant difference between the 2 curves (log-rank test = 0.001). Kaplan–Meier estimates of disease-free survival stratified by CI results showed a marginally significant difference between CI-positive and CI-negative patients (log-rank test = 0.04). Conclusion: FDG PET can be used to improve prediction of the clinical outcome of previously treated breast cancer patients relative to what is achievable through CI alone.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201912010195247ZK.pdf | 673KB | download |